Treatment of relapsed/refractory multiple myeloma with thalidomide-based regimens: Identification of prognostic factors

Leukemia and Lymphoma

Volumn 45, Issue 11, 2004, Pages 2275-2279

  Anagnostopoulos, Athanasios ^a   Gika, Dimitra ^a   Hamilos, George ^a   Zervas, Konstantinos ^b   Zomas, Athanasios ^c   Pouli, Anastasia ^d   Zorzou, Markela ^a   Kastritis, Efstathios ^a   Anagnostopoulos, Nikolaos ^c   Tassidou, Anna ^e   Anagnostou, Dimitra ^e   Dimopoulos, Meletios Athanasios ^a,f  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b THEAGENIO CANCER HOSPITAL   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d Agios Savvas Oncological Hospital   (Greece)

^e EVANGELISMOS HOSPITAL   (Greece)

^f NONE   (Greece)

Author keywords

Advanced myeloma; International staging system; Prognostic factors; Staging

Indexed keywords

ALBUMIN; BETA 2 MICROGLOBULIN; BORTEZOMIB; CLARITHROMYCIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; LACTATE DEHYDROGENASE; LENALIDOMIDE; THALIDOMIDE;

AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DATA ANALYSIS; DRUG RESPONSE; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL TIME;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANGIOGENESIS INHIBITORS; BETA 2-MICROGLOBULIN; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; MULTIPLE MYELOMA; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; REMISSION INDUCTION; THALIDOMIDE; TIME FACTORS; TREATMENT OUTCOME;

EID: 8644240941     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190410001733772     Document Type: Article

References (22)

1. Hayashi, T., Hideshima, T. and Anderson, K.C. (2003) "Novel therapies for multiple myeloma", Br. J. Haematol., 120, 10-17.
2. Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999) "Antitumor activity of thalidomide in refractory multiple myeloma", N. Engl. J. Med., 341, 1565-1571.
3. Barlogie, B., Desikan, R., Eddlemon, P., Spencer, T., Zeldis, J., Munshi, N., et al. (2001) "Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients", Blood, 98, 492-494.
4. Juliusson, G., Celsing, F., Turesson, I., Lenhoff, S., Adriansson, M. and Malm, C. (2001) "Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma", Br. J. Haematol., 109, 89-96.
5. Yakoub-Agha, I., Attal, M., Dumontet, C., Delannoy, V., Moreau, P., Berthou, C., et al. (2002) "Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the intergroupe francophone du myelome (IFM)", Hematol. J., 3, 185-192.
6. Weber, D., Rankin, K., Gavino, M., Delasalle, K. and Alexanian, R. (2003) "Thalidomide alone or with dexamethasone for previously untreated multiple myeloma", J. Clin. Oncol., 21, 16-19.
7. Schey, S.A., Cavenagh, J., Johnson, R., Child, J.A., Oakervee, H. and Jones, R.W. (2003) "A UK myeloma forum phase II study of thalidomide; long term follow-up and recommendations for treatment", Leuk. Res., 27, 909-914.
8. Dimopoulos, M.A., Zervas, K., Kouvatseas, G., Galani, E., Grigoraki, V., Kiamouris, C., et al. (2001) "Thalidomide and dexamethasone combination for refractory multiple myeloma", Ann. Oncol., 12, 991-995.
9. Palumbo, A., Giaccone, L., Bertola, A., Pregno, P., Bringhen, S., Rus, C., et al. (2001) "Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma", Haematologica, 86, 399-403.
10. Anagnostopoulos, A., Weber, D., Rankin, K., Delasalle, K. and Alexanian, R. (2003) "Thalidomide and dexamethasone for resistant multiple myeloma", Br. J. Haematol., 121, 768-877.
11. Moehler, T.M., Neben, K., Benner, A., Egerer, G., Krasniqi, F., Ho, A.D., et al. (2001) "Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy", Blood, 98, 3846-3848.
12. Garcia-Sanz, R., Gonzalez-Fraile, M.I., Sierra, M., Lopez, C., Gonzalez, M. and San Miguel, J.F. (2002) "The combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple myeloma", Hematol. J., 3, 43- 8.
13. Mileshkin, L.R., Biagi, J.J., Mitchell, P., Underhill, C., Grigg, A., Bell, R., et al. (2003) "A multi-centre phase-II trial of thalidomide in relapsed/refractory multiple myeloma reveals an adverse prognostic impact of advanced age", Blood, 13, 13.
14. Coleman, M., Leonard, J., Lyons, L., Pekle, K., Nahum, K., Pearse, R., et al. (2002) "BLT-D (Clarithromycin [Biaxin], Low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's Macroglobulinemia", Leukemia and Lymphoma, 43, 1777-1782.
15. Dimopoulos, M.A., Hamilos, G., Zomas, A., Gika, D., Efstathiou, E., Grigoraki, V., et al. (2004) "Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma", The Hematology Journal, 5, 112-117.
16. Greipp, P.R., San Miguel, J.F., Fonseca, R., et al. (2003) "Development of an International Prognostic Index (IPI) for myeloma: report of the International Myeloma Working Group", Hematol. J., 4(suppl 1), S42.
17. Blade, J., Samson, D., Reece, D., Apperley, J., Bjorkstrand, B., Gahrton, G., et al. (1998) "Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant", Br. J. Haematol., 102, 1115-1123.
18. Cox, D. (1972) "Regression models and life tables", J. R. Stat. SOC., 43, 187-220.
19. Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., et al. (2002) " Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma", Blood, 100, 3063-3067.
20. Richardson, P., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., et al. (2003) "A phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma", N. Engl. J. Med., 348, 2609-2617.
21. Dimopoulos, M.A., Barlogie, B., Smith, T.L. and Alexanian, R. (1991) "High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma", Ann. Intern. Med. 115, 931-935.
22. Barlogie, B., Smallwood, L., Smith, T. and Alexanian, R. (1989) "High serum levels of lactic dehydrogenase identify a high-grade lymphoma-like myeloma", Ann. Intern. Med., 110, 521-525.